Celltrion Pharm (068760) Financial Statements

OverviewFinancialsChecksFilings

In fiscal year 2025, Celltrion Pharm (068760) reported revenue of 536.4 billion KRW.

Income Statement

YearRevenueOp ProfitNet IncomeSource
2025536.4 billion KRW56.1 billion KRW38.8 billion KRW[source]
2024477.8 billion KRW37.2 billion KRW22.0 billion KRW[source]
2023388.8 billion KRW36.1 billion KRW21.3 billion KRW[source]
2022386.0 billion KRW38.2 billion KRW26.0 billion KRW[source]
2021398.7 billion KRW47.8 billion KRW34.6 billion KRW[source]

Balance Sheet

YearTotal AssetsTotal LiabilitiesTotal EquitySource
2025759.4 billion KRW323.5 billion KRW436.0 billion KRW[source]
2024669.5 billion KRW272.5 billion KRW396.9 billion KRW[source]
2023641.6 billion KRW265.0 billion KRW376.7 billion KRW[source]
2022599.7 billion KRW242.9 billion KRW356.8 billion KRW[source]
2021637.9 billion KRW305.9 billion KRW332.0 billion KRW[source]
Financials & Filings: DART (traceable by receipt number) · Prices: Financial Services Commission · Data Sources · Last checked: 2026-08-29 · About · Delisting market cap threshold: KOSPI 5B KRW / KOSDAQ 4B KRW (per listing rules) · This page provides factual information, not investment advice